Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Recruiting · NCT06206135 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
What this trial is about
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults 19 years of age or older as of the ICF date
- CKD patients undergoing hemodialysis to whom Nephoxil capsule shall be administered for the first time for the treatment of hyperphosphatemia as per the determination of the investigator
- Patients who voluntarily decide to participate in this study and complete the ICF
Exclusion criteria
- Those who fall under the "Do not administer to the following patients" criteria according to Nephoxil capsule indication approval
- Those who require concomitant administration of aluminum-containing medication
- Others determined by the investigator to be unsuitable for participation in this study
Where it is running
1 location listed.
- Jesus Hospital - Jeonju, South Korea